De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression.

Interestingly, comparison between control tumors and shp16 methotrexate-treated tumors was highly significant both at day 30 ( P = 0.002) and at the timepoint when all shp16 mice had reach endpoint (day 55, P < 0.001), although we do note variability in this experiment ( Supplementary Fig.

also in 132,142 other papers